Home   Business   Article

AI VIVO identified potential of Covid-19 treatment dexamethasone 10 weeks ago

AI VIVO says the success of dexamethasone as a Covid-19 therapy represents further validation of its artificial intelligence-powered engine, which identified the low dose steroid as a drug with high potential some 10 weeks ago.

Dexamethasone is now in use by the NHS after the national RECOVERY trial proved it cut the risk of death by a third for patients on ventilators, and by a fifth for those on oxygen.

Peyman Gifani, CEO of AI VIVO
Peyman Gifani, CEO of AI VIVO

AI VIVO identified the drug, and four others, as compounds most likely to be effective in treating the coronavirus back on April 16.

It used samples from Covid-19 infected cells to build a model for the disease, which was then used to rank thousands of compounds. Its AI-powered prediction engine took just 15 days to rank 90,000 compound models in order of efficacy and identified a shortlist.

It announced a wider list of 41 top-ranked candidates on May 7 that are currently in clinical trials.

Dr Peyman Gifani, AI VIVO founder and CEO, said: “This is another great validation of AI VIVO’s phenotypic approach to modelling diseases and the effects of drugs. We also believe there are combinations of other top-ranked drugs that with dexamethasone will be more effective than any single drug, and we are keen to share these combinations with pharma companies and clinical trial investigators to support the fight against Covid-19.

“We are expanding our interactions with government agencies and pharmaceutical companies to consider the top ranked drugs which have not yet been selected for trials, but have the potential to make a real difference in the fight against Covid-19.”

AI VIVO said it was in contact with clinical trial investigators including those in the UK’s ACCORD programme to provide insights for selecting the best drug combinations systematically.

The Cambridge company is planning to release the name of other generic top ranked drugs not currently in clinical trials on its website.

David Cleevely, lead investor of AI VIVO
David Cleevely, lead investor of AI VIVO

Dr David Cleevely, a lead investor in AI VIVO, said: “We are pleased to see that AI VIVO has once again been shown to have identified a breakthrough anti Covid-19 drug demonstrated to save lives around the world. This shows the unique capability of AI VIVO’s disruptive technology and the wider applications of this approach for other disease areas.”

Had dexamethasone been used to treat patients in the UK from the start of the pandemic, it is believed that up to 5,000 lives could have been saved.

The government has stockpiled 200,000 doses in case they are needed in a second wave of the virus.

AI VIVO says it has not disclosed a number of proprietary top ranked compound candidates in phase II or phase III clinical trials for other indications.

The company is contacting pharma companies who have developed these compounds to provide more information on why the compounds are top-ranked and how they might be used as single drugs and in combinations.

Read more

AI VIVO seeks collaborators as 41 of its top-ranked potential Covid-19 drugs enter trials

AI VIVO identifies list of 31 drugs that show potential for Covid-19 treatment

More by this author

This website and its associated newspaper are members of the Independent Press Standards Organisation (IPSO)

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More